Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment

Clinical Impact of Primary Tumor Location in Metastatic Colorectal Cancer Patients Under Later-Line Regorafenib or Trifluridine/Tipiracil Treatment

BackgroundPrimary tumor location (PTL) is an important prognostic and predictive factor in the first-line treatment of metastatic colorectal cancer (mCRC). Although regorafenib (REG) and trifluridine/tipiracil (FTD/TPI) have been introduced recently, the clinical impact of PTL in these treatments is...

Full description

Bibliographic Details
Main Authors: Hiromichi Nakajima, Shota Fukuoka, Toshiki Masuishi, Atsuo Takashima, Yosuke Kumekawa, Takeshi Kajiwara, Kentaro Yamazaki, Yuji Negoro, Masato Komoda, Akitaka Makiyama, Tadamichi Denda, Yukimasa Hatachi, Takeshi Suto, Naotoshi Sugimoto, Masanobu Enomoto, Toshiaki Ishikawa, Tomomi Kashiwada, Koji Ando, Satoshi Yuki, Hiroyuki Okuyama, Hitoshi Kusaba, Daisuke Sakai, Koichi Okamoto, Takao Tamura, Kimihiro Yamashita, Masahiko Gosho, Toshikazu Moriwaki
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-06-01
Series:Frontiers in Oncology
Subjects:
regorafenib
trifluridine/tipiracil
colorectal cancer
primary tumor location
biomarker
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.688709/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.688709/full

Similar Items